CXF Stock Overview A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Chimerix, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Chimerix Historical stock prices Current Share Price US$3.28 52 Week High US$3.35 52 Week Low US$0.66 Beta 1.03 1 Month Change 288.49% 3 Month Change 324.22% 1 Year Change 302.73% 3 Year Change -44.30% 5 Year Change 69.69% Change since IPO -76.67%
Recent News & Updates
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Dec 10
Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 3Q 2023) Nov 08
Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2023) Aug 14
Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024 Aug 06
Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Jul 05 See more updates
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Dec 10
Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 3Q 2023) Nov 08
Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2023) Aug 14
Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024 Aug 06
Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Jul 05
Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Jul 04
First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023) May 02
Chimerix, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024 Apr 26
Chimerix Appoints Marc D. Kozin to Board of Directors Mar 21
Full year 2023 earnings released: US$0.93 loss per share (vs US$1.97 profit in FY 2022) Mar 02
Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 23
Chimerix Announces Board Changes Dec 30 Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer Dec 05
Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer Dec 04
Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer Nov 17
Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022) Nov 03
Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
New minor risk - Share price stability Oct 17
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery Aug 17
New minor risk - Market cap size Aug 06
Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2022) Aug 03
Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29 Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index Jun 25
CEO, President & Director recently bought €90k worth of stock May 18
First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2022) May 05
Full year 2022 earnings released: EPS: US$1.97 (vs US$2.04 loss in FY 2021) Mar 03
Insufficient new directors Mar 01
Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study Dec 09
Rubric Capital Management Sends Letter to Chimerix Nov 11
Third quarter 2022 earnings released: EPS: US$2.75 (vs US$0.21 loss in 3Q 2021) Nov 04 Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million. Sep 27
Forecast to breakeven in 2022 Sep 07
Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.21 loss in 2Q 2021) Aug 09
Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 02
First quarter 2022 earnings released: US$0.28 loss per share (vs US$1.22 loss in 1Q 2021) May 17
Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million. May 17 Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022 May 10
No longer forecast to breakeven Apr 27
No longer forecast to breakeven Mar 05
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 03
Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 28
Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research Feb 25
Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research Jan 19
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020) Nov 05
Forecast to breakeven in 2023 Aug 09
Independent Director recently bought €65k worth of stock Jul 01
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox Jun 05
Forecast to breakeven in 2024 May 24
First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020) May 07
Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
Chimerix, Inc. Reports Topline Results from the First Cohort of Its Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study Feb 26
New 90-day high: €8.81 Feb 17
New 90-day high: €7.91 Jan 27
Chimerix, Inc. (NasdaqGM:CMRX) acquired Oncoceutics, Inc. from Spring Mountain Capital, LP and others for $68.3 million Jan 09
New 90-day high: €6.58 Jan 09
New 90-day high: €3.46 Dec 08
New 90-day high: €2.58 Nov 11
Revenue beats expectations Nov 06
Third quarter 2020 earnings released: US$0.18 loss per share Nov 06
Chimerix, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
New 90-day low: €1.93 Sep 17
New 90-day low - €2.22 Aug 29
New 90-day low - €2.47 Aug 11
First half earnings released Aug 10
Chimerix, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Aug 04 Shareholder Returns CXF DE Biotechs DE Market 7D 12.0% 3.1% 0.5% 1Y 302.7% -13.8% 7.2%
See full shareholder returns
Return vs Market: CXF exceeded the German Market which returned 7.2% over the past year.
Price Volatility Is CXF's price volatile compared to industry and market? CXF volatility CXF Average Weekly Movement 60.9% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CXF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CXF's weekly volatility has increased from 31% to 61% over the past year.
About the Company Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Show more Chimerix, Inc. Fundamentals Summary How do Chimerix's earnings and revenue compare to its market cap? CXF fundamental statistics Market cap €298.45m Earnings (TTM ) -€80.18m Revenue (TTM ) €152.50k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CXF income statement (TTM ) Revenue US$159.00k Cost of Revenue US$73.55m Gross Profit -US$73.39m Other Expenses US$10.21m Earnings -US$83.59m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.93 Gross Margin -46,154.72% Net Profit Margin -52,574.84% Debt/Equity Ratio 0%
How did CXF perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/28 14:24 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Chimerix, Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Geoffrey Meacham Barclays Jonathan Aschoff Brean Capital Ritu Baral Canaccord Genuity
Show 19 more analysts 
